

N-Terminal Pro–Brain Natriuretic Peptide Levels in Kawasaki Disease, Sepsis and Other Febrile Illnesses

PARAMITA BANERJEE,¹ PRIYANKAR PAL,¹ SWATI CHAKRAVARTI,¹ SURUPA BASU,² NAZNEEN AHMED¹

¹Department of Pediatric Medicine, Institute of Child Health, Kolkata, West Bengal.

²Department of Biochemistry, Institute of Child Health, Kolkata, West Bengal.

Correspondence to:

Dr Priyankar Pal, Professor,
Department of Pediatrics,
Institute of Child Health,
11, Dr Biresh Guha Street,
Kolkata 700 017, West Bengal.
mailme.priyankar@gmail.com

Received: Jun 2, 2022;

Initial review: Aug 17, 2022;

Accepted: May 27, 2023.

Objectives: To compare the values of N-Terminal Pro–Brain Natriuretic Peptide (NT-proBNP) in acute phase of Kawasaki disease (KD), sepsis and other acute febrile illnesses. **Methods:** We conducted a cross-sectional study on 40 KD patients and 40 age- and sex-matched controls with sepsis and other febrile illnesses between January, 2019 and June, 2020. Complete blood count, C-reactive protein (CRP), liver and renal function tests, serum electrolytes, chest X-ray, NT-proBNP level, Bactec blood culture, urine microscopy and culture along with detailed physical examination was done for all cases and control. **Results:** Mean (SD) values of NT-proBNP levels in acute KD was higher than sepsis/other febrile illnesses (914.9 (pg/mL) vs 219 (pg/mL); $P=0.001$). Also, the number of KD patients whose NT-proBNP was elevated were significantly higher compared to controls (70% vs 32.5%); $P<0.001$. **Conclusions:** NT-proBNP may be useful as a biomarker in the diagnosis of acute phase KD.

Keywords: Biomarker, Diagnosis, Infection, Myocardial stress.

Published online: July 20, 2023; PII: 097475591600563

Kawasaki disease (KD) is an acute self-limiting vasculitis predominantly affecting medium sized arteries. In the absence of specific diagnostic tests, diagnosis is based mainly on clinical criteria [1,2]. Due to overlapping clinical features, differentiation from sepsis and other inflammatory fevers of childhood becomes difficult. Thus we need to investigate for new markers which might help us to diagnose KD with certainty.

Brain-type natriuretic peptide (BNP) was first described in 1988 after isolation from porcine brain. Later it was found to originate mainly from the heart, representing a cardiac hormone [3]. NT-proBNP level rises in children with acute KD, but the mechanism is not clear [4,5]. Sepsis is a dreaded complication of severe trauma, extensive burns, shock, and other severe infections that result in multi-organ dysfunction. Affection of the cardiovascular system in sepsis leads to increased plasma NT-proBNP levels [6,7].

This study was undertaken to compare NT-proBNP levels in KD, sepsis and other febrile conditions to evaluate its utility, if any, as a biomarker in acute KD [8].

METHODS

This was a hospital based cross-sectional observational study conducted at a tertiary referral hospital in eastern

India. Children admitted between January, 2019 to April, 2020, with KD, sepsis and other febrile illnesses were included. Since the average number of KD admissions at the institute ranged between 35 to 40 in a year since 2015, and the study was over 16 months, we decided to enroll 40 KD patients presenting during the study period as the ‘case’ group. KD was diagnosed based on 2017 AHA (American Heart Association) criteria. The ‘control’ group comprised of another 40 children with sepsis or other febrile illnesses. Patients with structural heart disease, cardiomyopathy, renal failure, and those receiving chemotherapy/immunosuppressive therapy were excluded.

All patients had a complete blood count, C-reactive protein (CRP), liver and renal function tests, serum electrolytes, chest x-ray, NT-proBNP level, Bactec blood culture, urine microscopy and culture along with detailed physical examination. KD patients as well as those with suspected cardiac dysfunction had ECG and echocardiography. Blood samples were collected at admission before administering specific therapy. NTproBNP levels were measured by Cobas e411 (Roche Diagnostics) using electro-chemiluminescence immunoassay.

Institutional Ethics Committee clearance was taken prior to conducting the study. Since this was a pre-COVID study, patients with multi system inflammatory syndrome (MIS-C) were not included.

Statistical analysis: Data were entered into a Microsoft excel spread sheet and then analyzed by SPSS 27.0 (SPSS Inc.) and Graph Pad Prism version 5. We used two-sample *t* test for difference in mean, and chi-square test for difference in categorical variables. Correlation was calculated by Pearson correlation analysis. *P* value <0.05 was considered as statistically significant.

RESULTS

The median (range) age of 40 children with Kawasaki disease (21 boys) was 19 (3-108) months, and for the control group (24 boys), it was 44 (3-204) months. The mean (SD) duration of fever in Kawasaki disease was 7.8 (2.47) days, and 9.7 (2.36) days for the control group.

The control group comprised of 13 children with culture proven sepsis, 4 with pneumonia, 5 with enteric fever, 3 with systemic juvenile idiopathic arthritis, 2 with systemic lupus erythematosus, 3 with malaria, 4 with dengue, and the rest of the children had viral respiratory tract infections. Of the KD patients, 13 (32.5%) had coronary artery aneurysms at diagnosis, and 8 (20%) were intravenous immunoglobulin resistant.

Twenty eight (70.0%) patients in KD group had high NT-proBNP levels. In control group, 13 (32.5%) had high NT-proBNP and 27 (67.5%) had normal levels. Association of frequencies of patients having NT-proBNP level above and below cutoff value between KD and control group was statistically significant (*P*<0.001).

In KD, the mean (SD) NT-proBNP level was 914.91 pg/mL, whereas amongst controls the level was 219.03 pg/mL (*P*=0.001). NT-proBNP levels were found to be significantly positively correlated with platelet count and negatively correlated with leukocyte count, serum potassium and albumin levels (**Table I**). However, NT-proBNP levels with respect to echocardiographic findings/ IVIG resistance in the KD patients was not analyzed.

DISCUSSION

Diagnosis of KD depends on the recognition of a sequence of characteristic clinical findings. All clinical features may not be present at same time, and in the absence of a sensitive and specific pathognomonic laboratory test, diagnosis maybe difficult. Hence differentiation from sepsis and other autoimmune/inflammatory fevers of childhood becomes difficult [1]. The difficulty is more with incomplete and atypical presentations, consequently leading to a delayed diagnosis and increased risk of coronary artery involvement.

Several studies have explored the use of potential biomarkers to aid in the diagnosis of KD, NT-proBNP being one of the markers. Studies have shown the utility of this

biomarker in diagnosis of infantile and incomplete forms of KD [10,11], and also in predicting intravenous immunoglobulin (IVIg) resistance and coronary artery lesions [12,13].

BNP is synthesized as a pro-hormone (proBNP) by the myocardium. Myocardial ischemia, cytokines and endocrine (paracrine) modulation by other neurohormones are important stimulus for release of these molecules. Natriuresis or diuresis, peripheral vasodilatation, inhibition of the renin-angiotensin-aldosterone system and the sympathetic nervous system are the main physiological effects of BNP. NT-proBNP is mainly cleared from body by renal excretion, and the half-life is 120 mins.

Sepsis being a severe complication of many critical situations, early evaluation of its severity and initiation of proper treatment is important to reduce mortality. Procalcitonin, C-reactive protein, and activated protein C, are the known predictors. Recently NT-proBNP has been included in the list; increased levels being used as a marker of cardiac insufficiency secondary to sepsis and a poor prognostic indicator.

Based on the IAP (Indian Academy of Pediatrics) Position Paper on KD, we considered values of NT-proBNP above 225 pg/mL as significant [8]. As already mentioned, the number of patients with KD who had NT-proBNP levels above cutoff value was significantly more than the number in control group. This was consistent with the results of previous studies [14,15]. It was also shown that even patients with incomplete KD had higher NT-proBNP levels than febrile control group (84% vs 4%; *P*<0.001).

There are some limitations to our study. It was a cross-sectional, single centre study. Sample size was small and study subjects were enrolled from the inpatient department of

Table I Correlation Between NT-proBNP Level and Other Laboratory Parameters in Children with Kawasaki Disease (N=40)

| Parameters | Correlation coefficient | P value |
|--------------------------------|-------------------------|---------|
| Hemoglobin | 0.066 | 0.688 |
| Total leukocyte count | 0.315 | 0.048 |
| Platelet count | 0.469 | 0.002 |
| Erythrocyte sedimentation rate | 0.075 | 0.646 |
| C-reactive protein | 0.233 | 0.148 |
| Serum sodium | 0.110 | 0.500 |
| Serum potassium | 0.370 | 0.019 |
| Blood urea | 0.087 | 0.595 |
| Serum creatinine | 0.077 | 0.637 |
| Serum albumin | 0.660 | <0.001 |

WHAT THIS STUDY ADDS

- NT-proBNP measurement plays a significant role in the diagnostic algorithm of suspected kawasaki disease , even in patients with incomplete presentations.

a tertiary hospital, thereby raising the possibility of a referral bias. We did not analyze NT-proBNP values with respect to coronary artery dimensions. Future studies with a larger sample size and longitudinal design should be able to contribute more in the diagnostic importance of NT-proBNP in KD and generate cutoff values to distinguish KD and other fevers.

To ease diagnosis of KD and for timely initiation of immunoglobulin therapy, there is need for an early diagnostic test. Like previous studies from Northern India that explored the role of NT-proBNP in KD [14], we too state that NT-proBNP measurement may play a significant role in the diagnostic algorithm of suspected KD, even in patients with incomplete presentations.

Ethics clearance: Institutional Ethics Committee, Institute of Child Health, Kolkata; No. ICH/IEC/91/2018 dated Dec 29, 2018.

Contributors: PP: formulated and designed the study and provided statistical support; PB: conducted the study including preparation of proforma, data collection, blood sample collection and manuscript writing; SC: guided PB and assisted in writing the manuscript; SB: conducted the laboratory tests and interpreted them; NA helped PB in data collection and manuscript writing. All authors approved the final version of manuscript, and are accountable for all aspects related to the study.

Funding: None; *Competing interests:* None stated.

REFERENCES

1. Rawat A, Singh S. Biomarkers for diagnosis of Kawasaki disease. *Indian Pediatr.* 2015;52:473-4.
2. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation* 2004;110:2747-71.
3. Wiecek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation. *Am Heart J.* 2002;144:834-9.
4. Shiraishi M, Fuse S, Mori T, et al. N-terminal pro-brain natriuretic peptide as a useful diagnostic marker of acute Kawasaki disease in children. *Circ J* 2013;77:2097-01.
5. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and Nt-proBNP in clinical routine. *Heart.* 2006;92:843-9.
6. Li N, Zhang Y, Fan S, et al. BNP and NT-proBNP levels in patients with sepsis. *Front Biosci.* 2013;18:1237-43.
7. Burchardi H, Schneider H. Economic aspects of severe sepsis: A review of intensive care unit costs, cost of illness and cost effectiveness of therapy. *Pharmacoeconomics.* 2004;22:793-813.
8. Shenoy B, Singh S, Ahmed MZ, et al. Indian Academy of Pediatrics Position Paper on Kawasaki Disease. *Indian Pediatr.* 2020;57:1040-48.
9. Rodríguez-González M, Castellano-Martínez A, Alonso-Ojembarrena A. Usefulness of age-adjusted N-terminal prohormone of brain natriuretic peptide level as a diagnostic marker for incomplete Kawasaki disease in children. *Emergencias.* 2019;31:111-4.
10. Kang JH, Hong SJ, Seo IA, et al. Early detection of Kawasaki disease in infants. *Korean Circ J.* 2015;45:510-15.
11. Bae HK, Do Kyung Lee JH, Kim HS, et al. Clinical characteristics and serum N-terminal pro-brain natriuretic peptide as a diagnostic marker of Kawasaki disease in infants younger than 3 months of age. *Korean J Pediatrics.* 2014;57:357.
12. Shao, S., Luo, C., Zhou, K. et al. The role of age-specific n-terminal pro-brain natriuretic peptide cutoff values in predicting intravenous immunoglobulin resistance in Kawasaki disease: A prospective cohort study. *Pediatric Rheumatology.* 2019;17:65.
13. Zheng X, Zhang, Y, Liu L. et al. N-terminal pro-brain natriuretic peptide as a biomarker for predicting coronary artery lesion of Kawasaki disease. *Scientific Reports.* 2020; 10:5130.
14. Reddy M, Singh S, Rawat A, et al. Pro-brain natriuretic peptide (ProBNP) levels in north Indian children with Kawasaki disease. *Rheum Int.* 2016;36:551-9.
15. Dionne A, Dahdah N. A decade of NT-proBNP in acute kawasaki disease, from physiological response to clinical relevance. *Children (Basel).* 2018;5:141.